Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 9/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.56 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22419527 | 0.92 | NAMPT (0.70) | NAMPTHDAC3HDAC1HDAC2KCNJ1 | |
| SCHEMBL22419482 | 0.91 | NAMPT (0.74) | NAMPTHDAC3HDAC1HDAC2ALDH1A1 | |
| SCHEMBL22419484 | 0.89 | NAMPT (0.78) | NAMPTHDAC3HDAC1HDAC2MEN1 | |
| SCHEMBL22419489 | 0.86 | NAMPT (0.72) | NAMPTHDAC3HDAC1HDAC2ALDH1A1 | |
| SCHEMBL20953230 | 0.85 | NAMPT (0.73) | NAMPTHDAC3HDAC1HDAC2ALDH1A1 | |
| SCHEMBL20953281 | 0.85 | NAMPT (0.73) | NAMPTHDAC3HDAC1HDAC2CYP2C9 | |
| SCHEMBL21524191 | 0.84 | NAMPT (0.76) | NAMPTHDAC3HDAC1HDAC2CYP2C9 | |
| SCHEMBL20953233 | 0.84 | NAMPT (0.69) | NAMPTHDAC3HDAC1HDAC2CYP2C9 | |
| SCHEMBL21524211 | 0.83 | NAMPT (0.66) | NAMPTHDAC3HDAC1HDAC2MEN1 | |
| SCHEMBL30167830 | 0.83 | NAMPT (1.00) | NAMPTHDAC3HDAC1HDAC2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | NAMPT 1/4885HDAC3 89/4885HDAC1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.